The Pediatric Research Equity Act amends the federal Food, Drug, and Cosmetic Act to authorize the FDA to require pediatric studies of drugs or biologics when other approaches are insufficient to ensure that the products are safe and effective for use in children.
When was pediatric Research Equity Act enacted?
December 2003
The Pediatric Research Equity Act (PREA) was signed into law on December 2003 and reauthorized in 2007 and 2012. PREA mandates paediatric studies for new drugs or biologics which are required only on adult indication (s) under review.
What is a proposed pediatric study request?
A request made to FDA by a drug sponsor, leading to the issue of a Written Request by FDA. A Written Request (WR) is a legal document laying out the conditions under which a pediatric clinical trial should be conducted.
What is the race act?
The Research to Accelerate Cures and Equity (RACE) for Children Act aims to improve and expand treatment options for pediatric cancer patients by mandating that all new adult oncology drugs also be tested in children when the molecular targets are relevant to a particular childhood cancer.
What does Pdufa stand for?
Prescription Drug User Fee Act
The Prescription Drug User Fee Act (PDUFA) was created by Congress in 1992 and authorizes FDA to collect fees from companies that produce certain human drug and biological products.
What is a pediatric study plan?
An iPSP is an outline of the paediatric study or studies that the sponsor plans to conduct in the US – to confirm the suitability of drug usage in the paediatric population. Initial PSPs cover study objectives and design, age groups, relevant endpoints, and statistical approach.
What is pediatric exclusivity?
Pediatric exclusivity is an ADD-ON to existing marketing exclusivity or patent protection. In general, products with no patent life or exclusivity remaining cannot qualify.
What is the Creating Hope Act?
The Creating Hope Reauthorization Act incentivizes the pharmaceutical industry to develop treatments and cures for children with rare life-threatening conditions, including cancer, through an extension of the rare pediatric disease priority review voucher program at the U.S. Food and Drug Administration (FDA).
How much does it cost to file an IND?
FY 2014 – FY 2017
| Submission Type | FY 14 | FY 15 |
|---|---|---|
| Drug Applications | ||
| IND | $459.0 | $550.3 |
| NDA Clinical Data – NME | $5,646.4 | $5,250.5 |
| NDA with Clinical Data – Non-NME | $1,845.2 | $1,356.2 |
What is FDA action date?
The action date tells when an FDA regulatory action, such as an original or supplemental approval, took place. FDA Application Number. This number, also known as the NDA (New Drug Application) number, is assigned by FDA staff to each application for approval to market a new drug in the United States.
What is a pediatric written request?
Description of FDA’s Written Request Issuance of a Written Request to a sponsor does not require the sponsor to conduct pediatric studies described in the Written Request. It is the sponsor’s decision whether to conduct the studies and possibly gain pediatric exclusivity.
What is a rare pediatric disease priority review voucher?
Priority review voucher is awarded to a drug company if the company develops a drug for a rare pediatric disease and the drug is approved. The voucher allows the company to expedite the FDA review of a future drug. The company may sell the voucher to other companies that want to expedite drug reviews.
How long does IND approval take?
The IND must make a decision on your application for review within 6 weeks. The decision period of 6 weeks always starts on the last day on which you are able to submit an application for review. Even if you submit the application for review earlier. This decision period can be extended by a maximum of 6 weeks.
When IND is filed?
Treatment IND is submitted for experimental drugs showing promise in clinical testing for serious or immediately life-threatening conditions while the final clinical work is conducted and the FDA review takes place.
What is the purpose of FDA user fees?
Background and Legislation The Prescription Drug User Fee Act (PDUFA) was created by Congress in 1992 and authorizes FDA to collect fees from companies that produce certain human drug and biological products. Since the passage of PDUFA, user fees have played an important role in expediting the drug approval process.
What is FDA written request?
Description of FDA’s Written Request A Written Request is a specific document from FDA that is signed by the applicable office director(s) in which the Agency requests submission of certain studies to determine if the use of a drug could have meaningful health benefits in the pediatric population.
What is a rare pediatric disease?
A rare pediatric disease is one that is serious or life-threatening in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years, including neonates, infants, children, and adolescents.
How much is a priority review voucher worth?
sold a PRV for a drug for a rare pediatric disease to AbbVie Inc. for $350 million. In 2016–2018, the value of a voucher ranged from $125 million to $200 million, down from its peak in 2015.
What happens after IND approval?
Once an IND application is in effect, a drug manufacturer may ship the investigational new drug to the investigator(s) named in the application. An investigator may not administer an investigational new drug to human subjects until the IND application goes into effect.
What is an FDA written request?
What is FDA PREA?
PREA gives FDA the authority to require pediatric studies in certain drugs and biological products. Studies must use appropriate formulations for each age group. The goal of the studies is to obtain pediatric labeling for the product. Non-Compliance Letters under 505B(d)(1) of the Federal Food, Drug, and Cosmetic Act.
What is Fdara?
On August 18, 2017, the FDA Reauthorization Act (FDARA) (Public Law 115-52) was signed into law. FDARA amends the Federal Food, Drug, and Cosmetic Act (FD&C Act) to revise and extend the user fee programs for human drugs, biologics, generic drugs, medical devices, and biosimilar biological products.
What is gain exclusivity?
Non-patent exclusivities, such as GAIN exclusivity, provides 5 years of additional protection to the approved antibacterial and antifungal drugs to prevent generic entry into the market3,4. Lastly, the CDC helps in promoting education, innovation, and implementation of antibiotics stewardship programs.
What is written request?
Written Request means a writing that asks for information, and includes a writing transmitted by facsimile, electronic mail, or other electronic means.
What does the Pediatric Research Equity Act do?
Pediatric Research Equity Act (PREA) PREA gives FDA the authority to require pediatric studies in certain drugs and biological products. Studies must use appropriate formulations for each age group. The goal of the studies is to obtain pediatric labeling for the product.
What do you need to know about the PREA?
PREA gives FDA the authority to require pediatric studies in certain drugs and biological products. Studies must use appropriate formulations for each age group. The goal of the studies is to obtain pediatric labeling for the product.
What are the requirements for a pediatric research study?
Studies must use appropriate formulations for each age group. The goal of the studies is to obtain pediatric labeling for the product. Fulfills requirement that FDA post the PREA Non-Compliance letter and sponsor’s response. To view PREA postmarket requirements, check the Pediatric Research Equity Act box in the ‘Required Under’ section.
Is the FDA required to post a PREA non-compliance letter?
Fulfills requirement that FDA post the PREA Non-Compliance letter and sponsor’s response. To view PREA postmarket requirements, check the Pediatric Research Equity Act box in the ‘Required Under’ section.
